Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination

Abstract

Few cases of human papillomavirus (HPV) diseases have been reported in multiple sclerosis (MS) patients treated with fingolimod. We describe a case series of 16 MS patients (11 women, 5 men) developing HPV lesions after the onset of fingolimod, without previous HPV history. Fingolimod had to be discontinued in six patients. Six patients received vaccination for HPV, with good tolerance. Our report highlights that systematic HPV screening and discussion about HPV vaccination before fingolimod onset are crucial. In case of occurrence of HPV lesions during fingolimod treatment, a comprehensive workup of HPV disease is necessary, with discussion of HPV vaccination to prevent secondary lesions. Prevalence studies of HPV lesions are needed in MS patients with the different disease-modifying therapies.

Keywords

Human papillomavirus multiple sclerosis fingolimod vaccination

Get full access to this article

View all access options for this article.

References

Kappos

Radue

E-W

O’Connor

, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 387–401.

Triplett

Kermode

Corbett

, et al. Warts and all: Fingolimod and unusual HPV-associated lesions. Mult Scler 2019; 25(11): 1547–1550.

Khan

A case of numerous cutaneous warts on commencing fingolimod therapy for relapsing-remitting multiple sclerosis and review of the literature. In: Proceedings of the 99th annual meeting of the British Association of Dermatologists (BAD), Liverpool, 2–4 July 2019.

Benedetti

Marangi

Bozzetti

, et al. HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod. Mult Scler Relat Disord 2018; 23: 24–26.

Durrieu

Dardonville

Clanet

, et al. Cervical dysplasia in a patient with multiple sclerosis treated with natalizumab. Fundam Clin Pharmacol 2019; 33(1): 125–126.

Jaafar

Zeineddine

Massouh

, et al. Skin warts during fingolimod treatment in patients with multiple sclerosis. Mult Scler Relat Disord 2019; 36: 101437.

Couverture vaccinale HPV. 2018, https://www.santepubliquefrance.fr/determinants-de-sante/vaccination/articles/donnees-de-couverture-vaccinale-papillomavirus-humains-hpv-par-groupe-d-age (2020, accessed 30 November 2020).

Grimaldi-Bensouda

Rossignol

Kone-Paut

, et al. Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. J Autoimmun 2017; 79: 84–90.

Olsson

Kjaer

Sigurdsson

, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009; 5(10): 696–704.

10.

Joura

Garland

Paavonen

, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: Retrospective pooled analysis of trial data. BMJ 2012; 344: e1401.